secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001628280-23-011672
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma's Caldolor expected to qualify for separate Medicare reimbursement under NOPAIN Act from 2025
--------------------------------------------------------------------------------

- NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid pain management products in outpatient hospital and ambulatory surgical center settings.
- Caldolor (ibuprofen injection) is a non-opioid analgesic indicated for pain management, shown to reduce opioid use.
- Reimbursement applies to products furnished between Jan 1, 2025 and Jan 1, 2028; CMS to issue regs in 2024.
- Caldolor is FDA approved for mild to severe pain in adults and pediatric patients age 6 months+.
- Company expects this will positively impact Caldolor's Medicare reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023011672/0001628280-23-011672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023011672/cpix-20230414.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-011672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer